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1. Introduction 
Approximately 170 million persons worldwide are infected with the hepatitis C (HCV) 
virus. The incidence of glomerulonephritis in HCV-infected patients is unknown due to a 
lack of large-scale cross sectional surveys however subclinical renal involvement is believed 
to be highly prevalent among patients with HCV hepatitis. The most common HCV-
associated glomerulonephritis is membranoproliferative glomerulonephritis (MPGN) type 1 
with or without cryoglobulinaemia. MPGN typically presents several years, and often 
decades, after initial infection with HCV. Most patients have laboratory evidence of 
hypocomplementaemia, circulating rheumatoid factors, and cryoglobulinaemia. Other 
uncommon forms of glomerular disease that have been reported to be associated with HCV 
infection include membranous nephropathy, IgA nephropathy, focal segmental 
glomerulosclerosis, fibrillary glomerulonephritis/immunotactoid glomerulopathy, pauci-
immune glomerulonephritis, and thrombotic microangiopathy.  
The principal clinical manifestations of glomerular disease in HCV patients are the presence 
of proteinuria and microscopic haematuria with or without impaired kidney function. The 
clinical course of these HCV-associated glomerulopathies is generally characterised by 
remission and relapsing phases. The overall prognosis for HCV-associated 
glomerulonephritis remains poor, not only because of renal disease progression but because 
of the high incidence of cardiovascular disease, infection and hepatic failure.  
The exact pathogenic sequence of injury that results in glomerulonephritis is not known. 
The prevailing theory is that glomerular injury results from deposition of circulating 
immune complexes that contain HCV antigens and anti-HCV antibody. Involvement of the 
innate immune system in HCV-associated MPGN has been suggested with demonstration of 
upregulation of Toll-like receptor 3.  
In establishing a link between HCV infection and the immune response targeting the 
glomerulus, antiviral, plasma exchange and immunosuppressive therapies have been used 
in patients. The use of antiviral therapy in HCV-positive patients with glomerulonephritis is 
targeted at eliminating the virus and reducing the generation of HCV-related antibodies and 
immune complexes. The data to support antiviral treatment for HCV-associated 
glomerulonephritis is limited, however interferon therapy may be superior to 
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immunosuppressive agents in HCV-associated cryoglobulinaemic glomerulonephritis in 
lowering proteinuria. Agents such as rituximab have also been shown to be efficacious in 
the treatment of HCV-associated cryoglobulinaemic glomerulonephritis.  
This chapter provides the reader with an overview of hepatitis C-associated 
glomerulonephritis that covers epidemiology, clinical manifestations, natural history, 
immunopathophysiology, and a review of the evidence underpinning current therapeutic 
approaches.  
Hepatitis C virus (HCV) is a leading cause of chronic liver disease in the world. The World 
Health Organization estimates that there are 170 million individuals with HCV infection 
and an incidence of 3–4 million new cases per year (WHO, 2000).  HCV infection leads to 
chronic liver disease, but also to extra-hepatic manifestations. These include mixed 
cryoglobulinaemia, lymphoproliferative disorders and renal disease. HCV infection has 
been reported in association with distinct histological patterns of glomerulonephritis.  
In this review, we will canvass the epidemiology, clinical manifestations, natural history, 
immunopathophysiology, and current therapies of HCV-associated glomerulonephritis, as 
well as cover issues around renal transplantation.  
2. Immunopathogenesis 
HCV is a single-stranded enveloped RNA virus. Its genome codes for a nucleocapsid core 
protein, envelope proteins, and a number of non-structural proteins. Glomerular injury due 
to HCV occurs as a result of the direct interaction of viral RNA and proteins with 
glomerular cells, as well as indirectly through immunological mediators such as immune 
complex deposition. 
The adaptive immune response to HCV infection includes both cellular and humoral 
pathways. Unlike the overt cytotoxic cellular T-cell response to infected hepatocytes in the 
liver, the mechanism of injury in glomerulonephritis appears predominantly due to 
circulating immune complex deposition. This humoral response to HCV infection 
includes the production of various antibodies against HCV protein antigens. To evade 
this, HCV displays antigenic variability resulting from lack of proofreading activity in the 
HCV RNA polymerase. Hypervariable regions are present particularly in the envelope 
protein E2 sequence. Combined with a high replication rate, this antigenic variability 
allows mutant virus strains to escape antibody binding. Thus in chronic HCV infection, 
HCV RNA persists in serum despite the presence of anti-HCV antibodies. The chronic 
simultaneous presence of both HCV antigens and anti-HCV antibodies is a fertile setting 
for the formation of circulating immune complexes. In addition, HCV-induced liver injury 
decreases the hepatic clearance of circulating immune complexes, prolonging their 
survival in the circulation. 
Often the anti-HCV antibodies have the properties of cryoglobulins, that is they precipitate 
at low temperatures. Serum cryoglobulins are present at low levels in up to 50% of chronic 
HCV infected patients, however symptomatic cryoglobulinaemia occurs in 1% or less of 
patients and usually only after years of chronic infection (Meyers et al., 2003). In HCV 
infection, the cryoglobulins are almost always of mixed type, with type 2 (monoclonal 
rheumatoid factor usually IgM kappa) more common than type 3 (polyclonal rheumatoid 
factor) (Miller and Howell, 2000). Possibly, IgM directed against epitopes of the HCV 
envelope cross-reacts with IgG, forming the rheumatoid factor (Alpers and Kowalewska, 
2007). Thus, the cryoglobulins in HCV infection are composed of HCV RNA and/or 
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proteins, complexed with anti-HCV IgG, in turn complexed to IgM rheumatoid factor. The 
concentration of HCV RNA in cryoprecipitates has been found to be around 1,000 times 
higher than in serum (Kamar et al., 2008). While symptomatic cryoglobulinaemia is 
relatively rare in HCV infected patients, conversely the vast majority (over 80%) of patients 
with mixed cryoglobulins have evidence of HCV infection (Kamar et al., 2008). 
Circulating immune complexes, including cryoglobulins, deposit in glomeruli along the 
capillary walls and in the mesangium. IgM kappa rheumatoid factor has a particular affinity 
for cellular fibronectin in the mesangial matrix (Perico et al., 2009). While immunoglobulins 
are readily and routinely identified in glomerular tissues, the demonstration of HCV 
antigens in glomeruli is controversial and limited to relatively small numbers of studies. For 
example, Sansonno and colleagues (2005) used laser capture microdissection combined with 
PCR to identify HCV RNA in glomeruli, as well as immunohistochemistry to identify HCV 
core protein in glomeruli. Virus-like particles have been identified by electron microscopy in 
renal biopsies of patients with HCV infection (Sabry, 2002). 
While much work has focused on humoral immunity and immune complex deposition, 
there has also been research on the innate immune response of the glomerulus to HCV. This 
innate immune response to microbes involves Toll-like receptors (TLRs), transmembrane 
proteins that recognise microbial antigens. Dolganiuc and colleagues (2004), using a variety 
of human and mouse cell types, found that HCV core protein and HCV non-structural 
protein 3 act via Toll-like receptor 2 (TLR2) to trigger inflammatory pathways. In the kidney, 
it is also hypothesized that HCV RNA is recognised by Toll-like receptor 3 (TLR3) expressed 
on mesangial cells. Using a microdissection technique, increased TLR3 mRNA expression 
has been demonstrated in glomeruli with HCV-associated glomerulonephritis, compared to 
glomeruli with non-HCV-associated glomerulonephritis (Wornle et al., 2006). Recognition of 
HCV by TLR3 with subsequent intracellular signalling activates mesangial cells to produce 
pro-inflammatory cytokines and growth factors. The cytokines involved include TNFalpha 
and the chemokine IP-10 (interferon gamma inducible protein-10), both of which are 
upregulated in HCV-associated glomerulonephritis (Merkle et al., 2011). 
The innate immune response, together with the trapping and deposition of immune 
complexes, both contribute to generate activation of local inflammatory and complement 
cascades in glomeruli. These cascades induce glomerular cell proliferation and matrix 
production as well as the recruitment of inflammatory cells, which can be seen 
morphologically as the characteristic histological patterns of glomerulonephritis. While 
some morphological patterns are characteristic of HCV, none is specific, and the diagnosis of 
HCV-associated glomerulonephritis relies on correlation with clinical findings as well as the 
presence of serum anti-HCV antibody and HCV RNA. Evidence of HCV RNA and/or core 
protein in glomeruli has been identified irrespective of the histological pattern of 
glomerulonephritis (Sansonno et al., 2005). 
Membranoproliferative glomerulonephritis (MPGN) type 1 with or without 
cryoglobulinaemia is the most characteristic pattern, comprising the large majority (roughly 
80%) of all HCV-associated glomerulonephritis. Conversely, HCV is perhaps the most 
important cause of secondary MPGN. Histologically, the glomeruli have a 
membranoproliferative pattern with accentuated lobularity, mesangial hypercellularity, and 
mesangial interpositioning causing double contouring of the capillary walls. The glomeruli 
may have prominent inflammatory cell infiltration, particularly of monocytes (Alpers and 
Kowaleska, 2007).  See Figure 1 
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Fig. 1a. Membranoproliferative glomerulonephritis in a HCV-infected patient, with 
accentuated lobularity, mesangial hypercellularity and intracapillary mononuclear 
inflammatory cells (H&E, 400x). 
 
 
Fig. 1b. Double contouring of the capillary basement membranes is more evident on silver 
staining (Modified Wilder's silver stain, 400x). 
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Immunofluorescence staining highlights granular deposits of C3 and immunoglobulins 
(usually IgG and IgM) along capillary walls and in the mesangium, and electron microscopy 
confirms electron-dense immune complex deposits in subendothelial and mesangial locations. 
Cryoglobulin deposits themselves also produce a membranoproliferative pattern of injury. 
In these cases with cryoglobulinaemia, the deposits themselves may be seen histologically as 
eosinophilic glomerular capillary ‘hyaline thrombi’.  See Figure 2 
 
 
Fig. 2. Cryoglobulinaemic glomerulonephritis, with prominent intracapillary hyaline 
thrombi (H&E, 400x). 
In a minority of cases, vasculitis of small vessels can also be seen on biopsy. 
Immunofluorescence staining reflects the composition of the usually mixed-type 
cryoglobulin precipitate, with strong staining for IgG, IgM and C3 as well as frequent kappa 
predominance. The cryoglobulin deposits by electron microscopy have variable 
morphology, but classically are seen as microtubular and/or annular organised structures 
(Iskanda and Herrera, 2002) . See Figure 3 
MPGN type 3 has overlapping features of both MPGN type 1 in combination with 
membranous nephropathy, and has also been described as a pattern of HCV-associated 
glomerulonephritis. 
The remaining patterns of glomerulonephritis are relatively uncommon and have been 
reported as small series and case reports, with varying degrees of strength in their association 
with HCV. Of these relatively uncommon forms of HCV-associated glomerulonephritis, 
membranous nephropathy is the most often quoted. In a study by Yamabe and colleagues 
(1995), 2 of 24 patients (8.3%) with membranous nephropathy had evidence of HCV infection. 
A separate Japanese study of 2 patients with membranous nephropathy demonstrated 
pathogenic linkage to HCV by detecting HCV core protein in the affected glomeruli using 
immunofluorescence (Okada et al., 1996). In contrast to HCV-associated MPGN, HCV-
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associated membranous nephropathy does not appear associated with cryoglobulinaemia, 
rheumatoid factor or hypocomplementaemia (Uchiyama-Tanaka et al., 2004).  
 
 
 
 
Fig. 3. (3a above and 3b below). Cryoglobulin deposits classically show organised 
substructure such as microtubular aggregates (EM; photos courtesy of Mr Paul Kirwan, EM 
unit Concord Repatriation General Hospital Sydney Australia). 
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A case series from the University of Alabama at Birmingham examined the kidney biopsies 
of 30 patients receiving liver transplants for HCV-induced cirrhosis at the time of liver 
engraftment (McGuire et al., 2006). Three types of disease were observed: 
membranoproliferative glomerulonephritis type 1, IgA nephropathy, and “mesangial 
glomerulonephritis”. Cryoglobulins were not detected, even in rheumatoid factor-positive 
patients with urinary abnormalities.  
Other rare, somewhat speculative, reported associations with HCV include focal segmental 
glomerulosclerosis (Stehman-Breen et al., 1999), fibrillary glomerulonephritis/immunotactoid 
glomerulopathy (Markowitz et al., 1998), pauci-immune glomerulonephritis (Usalan et al., 
1998), and thrombotic microangiopathy (Herzenberg et al., 1998). 
Lastly, it should be noted that the development of de novo immune complex 
glomerulonephritis in the transplanted kidney is one mechanism leading to the increased 
graft failure seen in HCV-infected renal transplant recipients (Scott et al., 2010). 
3. Clinical manifestations 
Glomerulonephritis can develop several years or even decades after initial infection with 
HCV. As described previously the principal renal manifestation of HCV infection is 
membranoproliferative glomerulonephritis (MPGN). This is usually accompanied by 
cryoglobulinaemia. Classically, HCV-associated MPGN is found in persons with long-
standing infection and patients most often display mild subclinical liver disease. MPGN is 
rarely found in children. Clinically, patients may exhibit symptoms of cryoglobulinaemia, 
including palpable purpura, arthralgias, myalgias, neuropathy, and fatigue. The triad of 
purpura, peripheral neuropathy and arthralgia is evident in nearly 30% of cases (Monti et 
al., 1995). The majority of cryoglobulinaemic HCV-infected patients however have either no 
symptoms or nonspecific clinical manifestations. Cryoglobulins, or immunoglobulins (Igs) 
that precipitate at cold temperature, are detected in approximately 50–70% of patients. 
Cryoglobulinaemic vasculitis, predominantly involving the small vessels, is observed in less 
than 10% of patients (Lamprecht et al., 1999). The most frequently affected tissues/organs 
are skin, nerves, and kidney. Renal involvement has been reported in about one-third of 
cryoglobulinaemic patients (Meyers et al., 2003), but the predilection for renal involvement 
in certain patients is unclear. Renal signs of cryoglobulinaemia include nephrotic or non-
nephrotic proteinuria and microscopic haematuria with mild to moderate renal insufficiency 
(Baid et al., 2000; Johnson et al., 1993; Markowitz et al., 1998). Glomerular disease may 
manifest acutely as oliguric acute renal failure in 5% of cases (Meyers et al., 2003). Around 
80% of patients develop hypertension (Tarantino et al., 1995) which can be severe and 
difficult to control.  
Usually, the diagnosis of HCV-associated MPGN is made by positive tests for serum HCV 
antibodies and HCV RNA. However patients with HCV-associated glomerulonephritis in 
whom HCV RNA were not detected in the blood have been reported (Yamabe et al., 2010).  
Serum aminotransferase levels are increased in the majority of patients and often low serum 
concentrations of complement components (C1q, C4, and C3) are found (Meyers et al., 2003). 
Elevated levels of serum cryoglobulins can be divided by the Brouet classification into three 
types (Brouet et al., 1974). Type 2 and 3 cryoglobulins which are strongly associated with 
hepatitis C, have rheumatoid factor activity and bind to polyclonal immunoglobulins (Ferri 
et al., 2002). These two types are known as mixed cryoglobulinaemia.  
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4. Natural history  
A large prospective cohort study conducted in Northern Norway on 1010 HCV-positive 
patients found elevated alanine aminotransferases in 27.4%, decompensated liver disease in 
2.9%, hepatocellular carcinoma in 0.4% but only 2 patients (or 0.2%) with end-stage renal 
failure caused by membranoproliferative glomerulonephritis (Kristiansen et al., 2010). The 
median observation period from estimated acquisition of the disease to follow-up in these 
patients was 26 years.  
The long-term outcome of HCV-associated nephropathies is nebulous. A retrospective 
cohort study of 474,369 adult veterans in the United States (Tsui et al., 2007) found that 
patients with HCV infection were more likely to develop end-stage renal disease (4.3 per 
1000 person year) than HCV-seronegative patients (3.1 per 1000 person year). For patients 
aged 18 to 70 years with an estimated glomerular filtration rate of at least 30 mL/min per 
1.73 m2, HCV seropositivity was associated with a nearly threefold higher risk of 
developing ESRD (adjusted hazard rate, 2.80; 95% confidence interval, 2.43-3.23). 
Another cross-sectional study (Dalrymple et al., 2007) showed that HCV-positive veterans 
after adjustment for age, race, gender, diabetes and hypertension, had 40% higher odds for 
renal insufficiency (odds ratio 1.40; 95% confidence interval 1.11 to 1.76) as compared with 
HCV-negative veterans.  
An early literature review of patients with essential mixed cryoglobulinaemia (Ponticelli et 
al., 1986) found that of 11 patients with nephrotic syndrome and renal dysfunction who 
received supportive treatment alone, 4 patients (36%) died or exhibited progressive renal 
failure, 2 patients (18%) had stable renal disease, and spontaneous improvement occurred in 
the other 5 patients (45%).  
Finally Tarantino and colleagues (1995) reported the overall poor clinical outcome of 105 
essential mixed cryoglobulinaemia patients with renal involvement collected throughout 25 
years in three renal units in Milan. Patient survival was 49% at 10 years after renal biopsy. 
Forty-two patients died primarily from cardiovascular disease, liver disease or infection, 
whereas 15 patients developed chronic renal failure. Two patients had a complete remission 
of the disease while 15 had a remission only of renal manifestations. Thirty-one patients 
were alive at the end of the study with persistent renal and extrarenal manifestations. Thus 
only a minority of patients eventually developed renal failure because most patients died 
from cardiovascular disease, liver disease or infection.  
5. Therapy 
5.1 Renoprotective therapies 
As hypertension, proteinuria, and progressive renal failure are the main clinical 
manifestations of HCV-associated chronic renal disease, it is essential that renoprotective 
therapies be instituted. Diuretics, renin–angiotensin system inhibitors (angiotensin-
converting enzyme inhibitors or angiotensin II receptor blockers), and lipid-lowering agents, 
have been proven to be beneficial in HCV patients with chronic renal disease (Chadban and 
Atkins, 2005; Ruggenenti et al., 2001; Ruggenenti et al., 2004). 
5.2 Immunosuppressive therapy  
High-dose methylprednisolone has been used to treat exacerbations of mixed 
cryoglobulinaemia for over 30 years (Tarantino et al., 1981; De Vecchi et al., 1983). In one of 
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the earlier studies (De Vecchi et al., 1983), 3 pulses of intravenous methylprednisolone (0.5-1 
gm each) was given for 3 consecutive days during episodes of acute renal function 
deterioration in 16 patients with essential mixed cryoglobulinaemia. The intravenous 
administration was followed by oral prednisone 0.5 mg/kg per day with a slow taper until 
withdrawal of steroids after 4-6 months. Intravenous methylprednisolone pulse therapy did 
have a dramatic effect on renal function with cumulative mean plasma creatinine values 
decreasing from 3.3  1.3 mg/dL to 2.2  0.7 mg/dL (p<0.001). Proteinuria levels were not 
found to be significantly changed as a result of therapy. The basal cryocrit level decreased 
after pulse therapy, however again this was not found to be significant.  
In one case report of rapidly progressive MPGN type 1 with HCV and nephritic syndrome, 
intravenous pulsed methylprednisolone appeared to be useful in establishing rapid 
remission but as antiviral therapy was used concurrently it is impossible to ascertain the 
effect of methylprednisolone alone (Ahmed et al., 2008). 
Unlike intravenous pulse steroid therapy, oral steroids however have not been found to be 
effective in the acute setting. Ponticelli and colleagues (1986) reported 27 patients with 
mixed cryoglobulinaemia and acute renal disease that were treated with oral corticosteroids 
alone or in combination with other cytotoxic agents. 10 patients (37%) died or showed 
progressively worsening renal function, 4 patients continued to have stable renal disease, 
and the other 13 patients (48%) had improved renal function. This does not appear to differ 
markedly from their reporting of the natural outcomes of such patients with supportive 
treatments alone.  
Indeed there are conflicting results on the use of oral steroids for HCV-associated MPGN. A 
Japanese study (Komatsuda et al., 1996) found that only 2 out of 6 patients with MPGN 
responded to steroids but paradoxically found that the serum titre of HCV RNA decreased 
in 5 out of 7 treated patients.  
Other studies have subsequently confirmed that HCV RNA levels increase with steroid 
exposure (Fong et al., 1994; Lake, 2003; McHutchinson et al., 1993).  
Cyclophosphamide has been used successfully in the treatment of HCV-infected patients 
with cryoglobulinaemia and progressive loss of kidney function due to MPGN. In one case 
report a patient with HCV-associated MPGN and progressive renal failure displayed 
disappearance of serum cryoglobulins and a marked improvement in creatinine clearance 
with the institution of cyclophosphamide (Quigg et al., 1995). However cyclophosphamide 
treatment similar to steroids produces a rise in HCV RNA levels.  
It is generally agreed that immunosuppressive medications do increase HCV RNA levels 
but their selective use does not appear to worsen the underlying hepatic disease (D’Amico 
and Fornaserieri, 2003). A review by D’Amico (1998) reported no evidence of acute liver 
damage in more than 100 treatment courses (steroids, cyclophosphamide, plasma exchange) 
in Italian patients with HCV-associated cryoglobulinaemic glomerulonephritis. 
The expert consensus currently is that in patients with HCV-associated renal disease, 
treatment of acute flares does require immunosuppressive therapy to preserve renal 
function however prolonged therapy does not confer any additional benefit (Campise and 
Tarantino, 1999).  
5.3 Antiviral therapy 
Antiviral therapy in the form of alpha interferon was first used in a small pilot study of 7 
patients with cryoglobulinaemic vasculitis in 1987, before the discovery of the critical role of 
HCV in its pathogenesis (Bonomo et al., 1987).  
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After a link was established between HCV infection and the occurrence of 
cryoglobulinaemic MPGN, a number of studies have examined the efficacy of antiviral 
treatment to achieve both sustained virological response (clearance of HCV from the serum 
for at least 6 months after completing an antiviral course) and to improve renal injury. The 
use of antiviral therapy in HCV-positive patients with glomerulonephritis is targeted at 
eliminating the virus and reducing the generation of HCV-related antibodies and immune 
complexes. 
In the early 1990s, standard recombinant alpha interferon (-IFN) was used by itself. The 
first prospective randomised controlled trial by Misiani and colleagues (1994) reported that 
15 out of 25 patients with HCV-associated type II cryoglobulinaemia receiving recombinant 
alpha-interferon had a complete clearance of hepatitis C viral RNA and that all these 
patients reported improvements in cutaneous vasculitis and renal function. There was no 
effect on proteinuria. Unfortunately after treatment with interferon alpha-2a was 
discontinued, viraemia and cryoglobulinaemia recurred in all 15 HCV RNA-negative 
patients. 
Johnson and colleagues (1994) reported the results of a prospective uncontrolled trial of 
fourteen patients receiving interferon alpha for 6 to 12 months. There was a significant 
reduction in proteinuria but no improvement in renal function. Although a good clinical 
response correlated with disappearance of HCV RNA from the serum during treatment, 
relapse of viraemia and renal disease was common after the completion of therapy.  
It was clear at this stage that alpha-interferon was useful but the optimal treatment strategy 
was yet to be defined.  
An advance came with the discovery that ribavirin played a synergistic role with an 
interferon-based regimen to increase the possibility that an on-treatment responder would 
become a sustained responder. Ribavirin monotherapy itself was found to be disappointing 
(Pham et al., 1998) although one case report referenced a patient with refractory nephritic 
syndrome secondary to HCV-associated membranous nephropathy who had a complete 
remission following the initiation of ribavirin monotherapy (Hu and Jaber, 2005).  
Small scale studies examined the combination of standard interferon plus ribavirin for HCV-
associated cryoglobulinaemic glomerulonephritis. Rossi and colleagues (2003) treated 3 
patients with HCV-associated cryoglobulinaemic glomerulonephritis with standard 
interferon and ribavirin for 12 months and showed that all had sustained virological 
response, with reductions in daily proteinuria and rheumatoid factor at the end of follow-
up. Brucheld and colleagues (2003) treated 7 patients with HCV and renal insufficiency (2 
patients with cryoglobulinaemic vasculitis, 4 patients with MPGN, 1 patient with focal 
segmental glomerulosclerosis) with a combination of interferon and ribavirin. 4 of the 7 
patients had maintained virological and renal remission. The frequency of haematuria and 
amount of proteinuria decreased after the course of antiviral treatment.   
The next important clinical breakthrough was the introduction of a polyethylene glycol side 
chain (pegylation) to the interferon to give it a much longer bioavailability, allowing for 
weekly injections rather than three injections per week. Pegylated interferon was shown to 
double the sustained viral response rate in hepatitis C treatment (Lindsay et al., 2001).  
Saadoun and colleagues (2006) carried out a study on 72 consecutive patients with HCV-
associated mixed cryoglobulinaemic vasculitis receiving recombinant interferon or 
pegylated interferon, both in combination with oral ribavirin. A complete clinical response 
of the cryoglobulinaemic vasculitis occurred in 45 patients, a sustained virologic response 
occurred in 42 patients, and cryoglobulins cleared in 33 patients. Compared with patients 
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treated with IFN alpha-2b plus ribavirin, those receiving PEG-IFN alpha-2b plus ribavirin 
had a higher sustained clinical (67.5% versus 56.3%), virologic (62.5% versus 53.1%), and 
immunologic (57.5% versus 31.3%) response, regardless of HCV genotype and viral load. 
Fabrizi and colleagues (2007) then undertook a meta-analysis looking at clinical controlled 
trials of the 2 treatments (antiviral versus immunosuppressive) for HCV-associated 
glomerulonephritis. Six studies involving 145 patients with HCV-associated 
glomerulonephritis were identified (Alric et al., 2004; Beddhu et al., 2002; Johnson et al., 
1994; Komatsuda et al., 1996; Mazzaro et al., 2000; Misiani et al., 1994). The primary 
endpoint was the frequency of patients with significant reduction in proteinuria (return of 
proteinuria to normal or decrease of >50%) at the conclusion of therapy. It was shown that 
standard interferon alpha therapy was more effective than immunosuppressive therapy in 
lowering proteinuria of patients with HCV-associated glomerulonephritis (OR 3.86, 95% CI 
1.44-10.33; P=0.007). However renal dysfunction was not significantly improved with either 
therapy (Fabrizi et al., 2007).   
This meta-analysis was methodologically flawed by the inclusion of studies where patients 
received immunosuppressive agents during antiviral treatment, making it difficult to 
ascertain the effect of each treatment alone.  
A later meta-analysis (Feng et al., 2011) examined the results before and after stable 
regimens of antiviral therapy in subjects with HCV-associated glomerulonephritis and 
compared the results of those subjects who achieved sustained virological response (SVR) to 
those that did not. Improvement of proteinuria and serum creatinine levels after antiviral 
therapy were taken as the end points of interest. Eleven clinical trials involving 225 patients 
were included in the meta-analysis. At the end of antiviral therapy, the mean decrease in 
proteinuria was 2.71 g/24 h [95% confidence interval (CI) 1.38-4.04, P < 0.0001]. The pooled 
decrease in mean serum creatinine levels was 0.23 mg/dL (95% CI 0.02-0.44, P = 0.03). 
Comparison of nonsustained virological response (nonSVR) to SVR groups demonstrated a 
significant mean difference of proteinuria decrease in the SVR group of 1.04 g/24 h (95% CI 
0.20-1.89, P = 0.02) but the serum creatinine decrease of 0.05 mg/dL was not significant (95% 
CI -0.33 to 0.43, P = 0.80).  
A limitation of this meta-analysis is the small number of study subjects making it difficult to 
perform subgroup analysis on the basis of cryoglobulinaemia or baseline proteinuria. 
Another weakness is the lack of randomized controlled trials (RCTs) of interferon alpha-
based therapy in HCV-associated glomerulonephritis. Indeed only 1 of the 11 studies in this 
analysis was an RCT (Misiani et al., 1994). 
Thus antiviral therapy based on interferon alpha can significantly decrease proteinuria and 
hence should be undertaken in patients with HCV-associated glomerulonephritis.  
It should be acknowledged that currently there are no long-term follow-up studies of 
antiviral therapy on HCV-associated glomerulonephritis patients. It is important to ascertain 
whether interferon alpha-based treatments can delay or halt the progression of chronic renal 
disease in the long term. This will require investment in large RCTs with longer durations of 
follow-up.  
5.4 Rituximab 
Treatment with interferon alpha in combination with ribavirin can suppress HCV RNA in 
50-60% of patients with a subsequent decrease in cryoglobulins. Many patients however fail 
to respond to interferon therapy and half the responders relapse.  
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Rituximab is a monoclonal antibody against the CD20 antigen on the cell surface of B 
lymphocytes. Rituximab can thus reduce rheumatoid factor-producing B lymphocytes, 
resulting in a reduction in cryoglobulin production. In recent years the concept of anti-CD20 
for mixed-type cryoglobulinaemia has emerged as an effective and safe treatment, inducing 
a rapid remission of disease activity (Sansonno et al., 2003; Zaja et al., 2003).  
One study examined 20 HCV-positive patients with mixed-type cryoglobulinaemia (who 
were refractory to interferon therapy) that were treated with rituximab 375 mg/m² weekly 
for 4 weeks (Sansonno et al., 2003). Patients had a follow-up period of 12 months. Sixteen 
patients (80%) had a complete response defined as a 75% or greater reduction in 
cryoglobulins and resolution of at least 2 major clinical signs and symptoms. In these 
patients, rituximab treatment resulted in a reduction in both the IgM and IgG components of 
the cryoglobulin. Only 1 of the 20 patients had nephritis that did not respond to treatment.  
Another study looked at the treatment of 15 patients with rituximab with a follow-up period 
of 9 to 31 months (Zaja et al., 2003). 12 patients were HCV-infected and 3 patients had mixed 
cryoglobulinaemia unrelated to HCV. All patients had early improvement in their 
cutaneous manifestations with rituximab however only 1 patient had complete resolution of 
the cryoglobulin at 6 months and only 3 lost their rheumatoid factor. It is worthwhile noting 
that in 7 of 8 patients, maintenance corticosteroids were successfully withdrawn by the 
second post-treatment month.  
Quartuccio and colleagues (2006) carried out a study where 5 patients with HCV-
associated mixed cryoglobulinaemia were treated with 4 weekly infusions of rituximab 
375mg/m² without accompanying steroids. Renal function improved within 2 months in 
all 5 cases treated. There were no relevant short-term or delayed side effects reported. 
However 3 out of 5 patients showed a recurrence of disease at 5, 7 and 12 months. A 
repeated cycle of rituximab infusion induced rapid remission of disease activity in 2 of 
these patients. Only one patient achieved persistent remission after a single cycle and thus 
the results of the study suggest the need for repeated rituximab administrations for 
adequate control of nephritis. The optimal dosage and frequency of rituximab 
administrations in HCV-associated mixed cryoglobulinaemia remains unclear as all 
studies to date have been based on the rituximab prescribing regimen used in non-
Hodgkin lymphoma (Coiffier et al., 1998).  
6. Renal transplantation and HCV-related renal disease  
It should be recognised that the most common cause of proteinuria and renal insufficiency 
after kidney transplantation in HCV-positive patients is not HCV-related damage but 
chronic allograft nephropathy (Cosio et al., 1996; Nampoory et al., 2001). Renal diseases that 
have been reported in HCV-infected patients after kidney transplantation include recurrent 
or de novo MPGN, membranous nephropathy, minimal change disease, thrombotic 
microangiopathy, acute transplant glomerulopathy, and chronic transplant glomerulopathy 
(Baid et al., 2000; Cruzado et al., 2001; Gallay et al., 1995; Gloor et al., 2007; Hammoud et al., 
1996; Morales et al., 1997; Roth et al., 1995).  
MPGN is the most commonly reported, with an incidence as high as 54% in HCV-positive 
renal transplant recipients (Cruzado et al., 2001; Hammoud et al., 1996; Roth et al., 1995). In 
these patients proteinuria or nephrotic syndrome is the commonest clinical presentation 
(Cruzado et al., 2001; Nampoory et al., 2001; Virgilio et al., 2001).  Serum cryoglobulins are 
very often detected (Roth et al., 1995).   
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Early studies on patient and graft survival in HCV-positive renal transplant recipients have 
concentrated on recurrent liver disease as causes of morbidity and mortality rather than 
examining recurrent renal disease or graft loss (Batty et al., 2001; Meier-Kriesche, 2001; 
Pereira and Levy, 1997). Small single centre studies have shown that both graft and patient 
survival are lower for HCV-positive than HCV-negative patients (Batty et al., 2001; Pereira 
and Levy, 1997).  
More recently two large population based studies have published long term results of 
patient and graft survival (Morales et al., 2010; Scott et al., 2010).  
The outcomes of a large cohort of renal transplant patients was reviewed recently using 
the Australian and New Zealand Dialysis and Transplant registry (Scott et al., 2010). 
Survival outcomes, causes of mortality, and causes of graft failure were examined. 140 
(1.8%) patients were HCV antibody positive. Patient survival among HCV antibody 
positive and HCV antibody negative groups was 77% versus 90% and 50% versus 79% at 5 
and 10 years respectively. The adjusted hazard ratio for patient death was 2.38 (95% CI 
1.69-3.37). Higher rates of death due to cardiovascular disease (adjusted hazard ratio 
2.74), malignancy (adjusted hazard ratio 2.52) and hepatic failure (adjusted hazard ratio 
22.1) were observed. 
A large national study in Spain used data on 4304 renal transplant recipients, 587 of them 
with HCV antibody collected over a long period (1990-2002), to estimate graft and patient 
survival at 4 years (Morales et al., 2010). 4-year graft survival was found to be significantly 
better in HCV-negative versus HCV-positive patients (94.4% versus 89.5%, P < 0.005). 
Patient survival was 96.3% in the entire group with a demonstrable difference between 
HCV-negative and HCV-positive patients (96.6% vs 94.5%, P < 0.05). HCV-positive patients 
were characterised as having more episodes of acute rejection, a higher degree of 
proteinuria with impaired renal function and a greater need for renal graft biopsies. In 
particular de novo glomerulonephritis and transplant glomerulopathy rates in HCV-positive 
and HCV-negative renal graft biopsies was 9.3% versus 5.2% and 11.4% versus 5.0% 
respectively.  
6.1 Hepatitis C treatment implications in renal transplantation 
A meta-analysis of 12 trials of interferon alpha-based therapy in 102 kidney transplant 
patients showed that sustained virological response is extremely variable ranging from 0-
50% with a variable and often extremely high drop-out rate (0% to 100%) (Fabrizi et al., 
2006). HCV genotype is an important determinant of sustained virological response with 
genotype 1 being the most resistant (Lock et al., 1999). Any conferred benefit on the 
underlying disease is mitigated by a 15-60% increased risk of acute cellular or vascular 
rejection (Baid et al., 2003; Fabrizi et al., 2006; Weclawiack et al., 2008).  Unfortunately graft 
rejection is often severe and resistant to steroid therapy (Fabrizi et al., 2006).  
Cessation of standard interferon therapy leads to a surge in hepatitis C viral load (104,105). 
Avoidance of interferon in HCV-positive renal transplant patients has been recommended 
because of the potential to precipitate acute graft rejection. However combined therapy with 
ribavirin and pegylated interferon achieved sustained virological response in 5 out of 8 
patients (62%) without unduly affecting renal function (Montalbano et al., 2007; Mukherjee 
and Ariyarantha, 2007; Schmitz et al., 2007). This suggests a therapeutic role in certain 
settings albeit with an appreciable risk of graft dysfunction.  
Rituximab appeared to be safe in one study of 7 HCV RNA-positive kidney transplant 
patients with de novo cryoglobulinaemia-related MPGN. HCV infection remained stable 
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during and after rituximab therapy (Kamar et al., 2007). Larger long-term studies will be 
necessary to establish efficacy.   
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